Search the Newsreel

ALKIM-KIMYA, ALKIM Bilanço

KALYON GUNES TEKNOLOJILERI (KLYPV) Hisse Senedi

DYO BOYA FABRİKALARI SANAYİ VE TİCARET A.Ş.(DYOBY) Sorumluluk Beyanı (Konsolide) 13 Ağustos 2026

Kalpataru Projects Bags New Orders Worth Rs 3,526 Crore

Kalpataru Projects secures ₹3,526 crore EPC and T&D orders in India

Kalpataru Projects International secures multiple orders worth ₹3,526 crore; shares down

KLYPV Hisse Yorumları (KALYON GUNES TEKNOLOJILERI Güncel Yorumlar)

Kalyani Investment Q1 Results: Standalone net profit up 16.6% YoY to ₹24.21 million

Results: Kalpataru Projects International Limited Beat Earnings Expectations And Analysts Now Have New Forecasts

Kalgoorlie Gold Mining completes cost-efficient aircore drilling at Pinjin’s LTZ Flexure

Kalyani Investment Company Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Kalyani Investment Q1 Results: Consolidated PAT turns positive, OCI surges

Kalaris Therapeutics Reports Q2 Financial Results, Advances Clinical Program

Kalaris Therapeutics announced its Q2 2026 financial results, reporting $93.5 million in cash, cash equivalents, and marketable securities, projected to fund operations into Q4 2027. The company is advancing its phase 1b/2 study of TH103 for neovascular age-related macular degeneration (AMD), with preliminary data …

Lords Chloro Alkali sets Sept 11 AGM date for board pay, borrowing approvals

Buy Kalpataru Projects International; target of Rs 1600: Motilal Oswal

Kalyani Steels Standalone June 2026 Net Sales at Rs 464.58 crore, up 4.93% Y-o-Y

Earnings call transcript: Gokaldas Exports Q1 2026 shares fall 4.7%

Kalaris Therapeutics, Inc. 2Q 2026: Net loss $(11.5M), Diluted EPS $(0.48) — 10-Q Summary

Kalaris Therapeutics, Inc. reported a net loss of $(11.5M) for 2Q 2026, which was essentially flat compared to the previous year, while diluted loss per share improved to $(0.48). The company has no product revenue, with results primarily driven by research and development, and …

Kalyan Jewellers India Shares Fall 2.19%, Company Declares Final Dividend of Rs 2.50 Per Share

Oyak Cimento Fabrikalari AS (OYAKC) Finans Oranları

Kalyani Forge makes Q1 FY27 investor meet recordings available online

Gokaldas Exports Q1FY27 income rises 21% to ₹1,180 crore

Kalyani Forge Q1 FY27: ROCE hits 22%, PAT surges 218% on margin expansion

Daily Brief India: Mrs Bectors Food Specialities, Kalyani Investment, Shiprocket, Knowledge Realty Trust, Encube Ethicals Limited, National Stock Exchange and more

Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates

Kalaris Therapeutics announced its Q2 2026 financial results, including $93.5 million in cash expected to fund operations into Q4 2027. The company is currently dosing patients in a Phase 1b/2 study for TH103, a treatment for neovascular Age-related Macular Degeneration, with preliminary data anticipated …

Gokaldas Exports Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Transcript : Kalpataru Projects International Limited, Q1 2027 Earnings Call, Aug 11, 2026

Kalaris Therapeutics Releases Q2 2026 Financial Results

Kalaris Therapeutics, Inc. (ALVR) reported a narrower loss for the second quarter of 2026, with a loss of $0.48 per share, improving 21.3% from the previous year. The company's net loss for the quarter was $11.5M, reflecting ongoing efforts to manage operating expenses while …

Kalaris Therapeutics (NASDAQ:KLRS) Announces Earnings Results

Earnings call transcript: Kalpataru Projects posts strong Q1 2026 results

Form 8K Kalaris Therapeutics Inc For: 11 August By Investing.com

The article reports that Kalaris Therapeutics Inc. filed a Form 8K on August 11, according to Investing.com. This filing is a significant event for the company, as 8K forms are used to announce unscheduled material events or corporate changes important to investors. The article …

Kalpataru Projects International Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

BRIEF-Kalaris Therapeutics Inc Q2 Operating Income USD -12.386 Million Vs. IBES Estimate USD -12.5 Million

Kalaris Therapeutics Inc reported a Q2 operating income of -$12.386 million. This figure is slightly better than the IBES estimate of -$12.5 million. The brief financial update indicates that the company's Q2 performance, while negative, exceeded analyst expectations.